Dividend-focused investing has long proven itself a reliable strategy to beat long-term market returns on Wall Street. Yet top dividend stalwarts usually attract swarms of income investors and trade at steep valuation premiums. Within the healthcare sector, two blue-chip drugmakers stand out as compelling exceptions: Pfizer (PFE) and Bristol Myers Squibb (BMY). Oversold on near-term headwinds and looming patent expirations, both firms boast robust cash generation, sustainable payout profiles and deep late-stage pipelines ripe for commercialization, offering attractive entry points for long-term income investors.
Their deep valuation discounts stem largely from overblown market pessimism over short-term risks. After scaling record $100 billion annual revenue in 2022 fueled by COVID-19 vaccines and antivirals, Pfizer saw its top line shrink as pandemic demand faded. Both PFE and BMY face patent cliffs for blockbuster therapies by the end of the decade, dragging their share prices far below the broader healthcare benchmark. As of July 2026, the S&P 500 healthcare sector carries an average forward P/E of 18.2x. Pfizer trades at just 8.2x forward earnings, while Bristol Myers sits at 9x, slashing more than half of the sector’s average multiple. Markets have fully priced in revenue erosion from expiring patents, overlooking resilient fundamentals and transformative R&D pipelines.
Neither stock qualifies as a value trap, though. Tight cost controls, recently launched commercial assets and multi-year drug development pipelines position both companies to offset patent-related revenue losses, supporting consistent, growing dividends even through industry downcycles.
PFE’s landmark COVID revenue boom has faded, and its shared blood thinner Eliquis is set to lose patent exclusivity later this decade, weighing on investor sentiment. Still, the pharmaceutical giant’s long-term growth narrative remains intact, anchored by an industry-leading pipeline weighted heavily toward oncology and metabolic disorders.
PF’4404, a novel bispecific antibody under Phase 3 evaluation, targets two cancer biomarkers simultaneously, outperforming conventional single-target monoclonal antibodies in early clinical readouts presented at the 2026 ASCO Annual Meeting. The candidate targets multiple high-value indications including non-small cell lung cancer, colorectal cancer and endometrial cancer, potentially evolving into a multi-indication blockbuster. Pfizer’s weight-loss drug portfolio also houses multiple Phase 3 assets, while recently commercialized products—bladder cancer treatment Padcev and RSV vaccine Abrysvo—are driving steady near-term revenue expansion over the next three to five years.
The stock delivers a forward dividend yield of 7.1%. Pfizer has lifted its shareholder payout for 15 consecutive years, marking a 51.3% total dividend hike over the past decade. Its manageable 56% payout ratio and consistent operating cash flow eliminate meaningful dividend cut risks. At current market prices, a $1,000 investment secures roughly 42 PFE shares, compounding long-term passive income.
Bristol Myers has already navigated a prior wave of patent losses and returned to modest revenue growth, yet investors remain wary of upcoming expirations for two cornerstone franchises: Eliquis and PD-1 checkpoint inhibitor Opdivo through 2027–2028. The biotech has laid comprehensive groundwork to replace these aging revenue drivers.
A subcutaneous formulation of Opdivo has secured regulatory approval, extending the drug’s commercial lifespan via improved patient administration. Its joint program with Johnson & Johnson, next-generation oral anticoagulant Milvexian, earned FDA Fast Track designation. While the asset missed primary endpoints for acute coronary syndrome, Phase 3 trials for atrial fibrillation and secondary stroke prevention remain underway, with top-line data slated for release in 2026. If successful, Milvexian could emerge as a safer successor to Eliquis with lower bleeding risks. Separately, BMY is co-developing bispecific antibody pumitamig with BioNTech, adding another high-potential candidate to its oncology pipeline. A lineup of newly launched hematology and immunology drugs will further cushion top-line declines from patent expirations.
BMY carries a 4.3% forward dividend yield, with total payout growth of 65.8% across the last 10 years. Streamlined debt obligations and ample cash reserves shield its dividend program from cuts. Its 9x forward earnings multiple hovers near historical troughs, and investors can purchase approximately 17 shares with a $1,000 allocation, fitting portfolios seeking steady income paired with valuation re-rating upside.
The steep discounts on Pfizer and Bristol Myers Squibb reflect excessive market pricing of temporary patent cycle risks, while ignoring their deep R&D portfolios, durable cash flow generation and track records of raising shareholder dividends. Upcoming clinical milestones and commercial launches across oncology, cardiovascular and respiratory franchises are poised to lift revenue projections and compress valuation gaps versus sector peers.
For investors prioritizing long-term recurring income, PFE and BMY deliver above-average dividend yields as downside protection alongside multi-year growth catalysts unique to leading biopharma names. The pair stand out as high-cost-efficiency dividend holdings amid the current U.S. healthcare market landscape.
